Sebivo demonstrated better antiviral activity compared to lamivudine in patients with hepatitis

Published: 2010-03-12 06:55:00

Updated: 2010-03-12 06:55:00

Handok Pharm announced on March 9 new clinical data of Sebivo (telbivudine) for 24 weeks of treatment of chronic hepatitis B (CHB). Handok is a co-distributor of Sebivo in Korea.

Data from the second year of the phase III GLOBE study in patients with 1,367 patients from 20 countries suggest th...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK